NewslettersNeural Cell NewsUS FDA Awards Orphan Drug Designation (OOD) to Paxalisib for AT/RT, a Rare Form of Childhood Brain CancerBy Bob - June 22, 20220126Kazia Therapeutics Limited announced that the US FDA has awarded ODD to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors, a rare and highly aggressive childhood brain cancer.[Kazia Therapeutics Limited]Press Release